Alkermes' ALKS 7290 Shows Clinically Meaningful ADHD Symptom Improvement in Phase 1b
ALKS sits 61% above its 52-week low of $26.99 on elevated volume (3.7× avg).
Summary
Alkermes reported positive Phase 1b results for ALKS 7290, its orexin 2 receptor agonist for ADHD. In 50 adults with ADHD, the drug produced dose-dependent reductions in AISRS scores (14.0 points at 20 mg, 19.0 at 50 mg) and CGI-S scores (1.0 and 2.0 points) after 14 days, with no serious adverse events. These are the first clinical data for an orexin agonist in ADHD and support the ongoing Phase 2 trial, which began dosing in September 2026. The results validate a novel mechanism and expand Alkermes' neuroscience pipeline beyond its commercial products. Phase 2 data will be the next major readout, though no timeline was provided.
At the time of this announcement, ALKS was trading at $43.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $26.99 to $55.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.